Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + liposomal irinotecan in recurrent or metastatic osteosarcoma (Phase 1–2, single-arm)
ChiCTR2600126711Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2026
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and nanoliposomal irinotecan in osteosarcoma (OS), sponsored by Peking University People's Hospital. Primary endpoint: Recommended Phase 2 Dose (RP2D). Started Jun 2026; status: recruiting.
02
Drugs
Rivoceranibnanoliposomal irinotecan
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR2600126711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126711.